{
    "root": "2f74965f-3c85-0590-e063-6294a90af267",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe and Simvastatin",
    "value": "20250303",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16918"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_76359"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        },
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9150"
        }
    ],
    "indications": {
        "text": "ezetimibe simvastatin ezetimibe simvastatin combination simvastatin ezetimibe indicated : \u2022 adjunct diet reduce elevated low density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies reduce elevated ldl-c adults homozygous familial hypercholesterolemia ( hofh ) . simvastatin simvastatin , used component ezetimibe simvastatin , indicated reduce risk total mortality reducing risk coronary heart disease death , non-fatal myocardial infarction stroke , need coronary non-coronary revascularization procedures adults established coronary heart disease , cerebrovascular disease , peripheral vascular disease , and/or diabetes , high risk coronary heart disease events .",
        "doid_entities": [
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "peripheral vascular disease (DOID:341)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_341"
            },
            {
                "text": "vascular disease (DOID:178)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_178"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "important information : ( 2.1 ) take ezetimibe simvastatin orally daily evening without food . maximum recommended ezetimibe simvastatin 10/40 mg daily . ezetimibe simvastatin 10/80 mg daily restricted patients taking ezetimibe simvastatin 10/80 mg daily chronically ( e.g . , 12 months ) without evidence muscle toxicity . patients require high-intensity statin unable achieve ldl-c goal receiving ezetimibe simvastatin 10/40 mg daily , prescribe alternative ldl-c-lowering treatment . dose missed , take missed dose soon possible . double next dose . assess ldl-c clinically appropriate , early 2 weeks initiating ezetimibe simvastatin , adjust necessary . adults : recommended range 10/10 mg 10/40 mg daily . ( 2.2 ) full prescribing information ezetimibe simvastatin modifications due . ( 2.3 ) patients renal impairment : doses exceeding 10/20 mg used caution close monitoring patients moderate severe renal impairment . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ezetimibe simvastatin tablets 10/40 , ( ezetimibe , usp 10 mg/simvastatin , usp 40 mg tablets ) white off-white , capsule shaped tablets debossed \u201c a027 \u201d one side plain side . ndc : 70518-1955-00 packaging : 90 1 bottle plastic storage store 20 25o c ( 68 77 ) . [ usp controlled room temperature . ] keep container tightly closed . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "ezetimibe simvastatin tablets contraindicated following conditions : concomitant strong cyp3a4 inhibitors ( select azole anti-fungals , macrolide antibiotics , anti\u00adviral medications , nefazodone ) [ ( 7.1 ) ] . concomitant cyclosporine , danazol , danazol [ ( 7.1 ) ] . acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity simvastatin , ezetimibe , excipients ezetimibe simvastatin tablets . hypersensitivity , including anaphylaxis , angioedema , stevens-johnson syndrome , reported [ ( 6.2 ) ] .",
    "indications_original": "Ezetimibe and Simvastatin\n                  \n                  Ezetimibe and simvastatin is a combination of simvastatin and ezetimibe indicated:\n                  \u2022 As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C):\n                  o In adults with primary hyperlipidemia.\n                  o In adults and pediatric patients aged 10 years and older with\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 heterozygous familial hypercholesterolemia (HeFH).\n                  \u2022 As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                  \n                     Simvastatin\n                  \n                  Simvastatin, when used as a component of ezetimibe and simvastatin, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.",
    "contraindications_original": "Important Dosage and Administration Information: (2.1) Take ezetimibe and simvastatin orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin 10/40 mg once daily. Ezetimibe and simvastatin 10/80 mg daily dosage is restricted to patients who have been taking ezetimibe and simvastatin 10/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ezetimibe and simvastatin 10/40 mg daily, prescribe alternative LDL-C-lowering treatment. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. Assess LDL-C when clinically appropriate, as early as 2 weeks after initiating ezetimibe and simvastatin, and adjust the dosage if necessary. Adults: Recommended dosage range of 10/10 mg to 10/40 mg once daily. (2.2) See full prescribing information for ezetimibe and simvastatin dosage modifications due to drug interactions. (2.3) Patients with Renal Impairment: Doses exceeding 10/20 mg should be used with caution and close monitoring in patients with moderate to severe renal impairment. (2.4)",
    "warningsAndPrecautions_original": "Ezetimibe and simvastatin tablets 10/40, (ezetimibe, USP 10 mg/simvastatin, USP 40 mg tablets) are white to off-white, capsule shaped tablets debossed with \u201cA027\u201d on one side and plain on other side.\n                  \n                  NDC: 70518-1955-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  Store at 20 to 25o\u00a0C (68 to 77\u00a0oF). [See USP Controlled Room Temperature.] Keep container tightly closed.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Ezetimibe and simvastatin tablets is contraindicated in the following conditions:\n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti\u00adviral medications, and nefazodone)\n  \n   [see Drug Interactions (\n   \n    7.1)]\n  \n   .\n \n  \n                     Concomitant use of cyclosporine, danazol, or danazol\n  \n   [see Drug Interactions (\n   \n    7.1)]\n  \n   .\n \n  \n                     Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   .\n \n  \n                     Hypersensitivity to simvastatin, ezetimibe, or any excipients in ezetimibe and simvastatin tablets. Hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, have been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]\n  \n   .",
    "drug": [
        {
            "name": "Ezetimibe and Simvastatin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_49040"
        }
    ]
}